Last edition
News about "Chia Tai Tianqing Pharmaceutical Group"
Cipla Partners with CTTQ to Develop and Commercialise HER2-Targeted ADC in Emerging Markets
Cipla and CTTQ partner to expand access to TQB2102, an investigational HER2 bispecific ADC being evaluated across HER2-expressing cancers.
Chia Tai Tianqing Pharmaceutical Group | 01/09/2026 | By News Bureau | 109
Four Drugs in Race for First Bispecific ADC Approval: GlobalData
With 21 global approvals, ADCs generated USD 13.6 billion in 2024. BsADCs represent further opportunities in this field, by leveraging bi-specific antibodies that simultaneously bind two distinct targets.
Chia Tai Tianqing Pharmaceutical Group | 02/09/2025 | By Dineshwori | 402
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy